Walter & Keenan Wealth Management LLC IN ADV Sells 258 Shares of Eli Lilly and Company (NYSE:LLY)

Walter & Keenan Wealth Management LLC IN ADV decreased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 1.0% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 25,488 shares of the company’s stock after selling 258 shares during the period. Eli Lilly and Company makes up approximately 6.9% of Walter & Keenan Wealth Management LLC IN ADV’s investment portfolio, making the stock its largest holding. Walter & Keenan Wealth Management LLC IN ADV’s holdings in Eli Lilly and Company were worth $22,581,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Azzad Asset Management Inc. ADV raised its stake in shares of Eli Lilly and Company by 2.5% in the first quarter. Azzad Asset Management Inc. ADV now owns 1,814 shares of the company’s stock worth $1,411,000 after purchasing an additional 45 shares during the last quarter. TCP Asset Management LLC purchased a new stake in shares of Eli Lilly and Company in the 1st quarter valued at $201,000. Valley National Advisers Inc. increased its stake in shares of Eli Lilly and Company by 2.9% in the first quarter. Valley National Advisers Inc. now owns 5,901 shares of the company’s stock worth $4,591,000 after acquiring an additional 165 shares during the period. Lake Street Private Wealth LLC lifted its position in Eli Lilly and Company by 5.7% during the first quarter. Lake Street Private Wealth LLC now owns 8,175 shares of the company’s stock valued at $6,360,000 after purchasing an additional 440 shares during the period. Finally, Meadow Creek Wealth Advisors LLC boosted its holdings in Eli Lilly and Company by 112.4% in the first quarter. Meadow Creek Wealth Advisors LLC now owns 4,161 shares of the company’s stock valued at $3,237,000 after purchasing an additional 2,202 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 6.3 %

Shares of LLY opened at $846.90 on Thursday. The firm’s fifty day moving average is $916.20 and its two-hundred day moving average is $865.10. The stock has a market cap of $804.90 billion, a PE ratio of 124.73, a price-to-earnings-growth ratio of 3.24 and a beta of 0.42. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74. Eli Lilly and Company has a 52-week low of $547.61 and a 52-week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing analysts’ consensus estimates of $1.53 by ($0.35). Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. The business had revenue of $11.44 billion during the quarter, compared to analyst estimates of $12.09 billion. During the same quarter in the previous year, the company posted $0.10 EPS. The firm’s revenue was up 20.4% on a year-over-year basis. Research analysts forecast that Eli Lilly and Company will post 14.05 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 0.61%. The ex-dividend date is Friday, November 15th. Eli Lilly and Company’s payout ratio is currently 76.58%.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Bank of America lifted their price objective on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the company a “buy” rating in a research note on Friday, August 9th. BMO Capital Markets boosted their price target on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a report on Friday, August 9th. JPMorgan Chase & Co. raised their price objective on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a research note on Friday, September 13th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $885.00 target price on shares of Eli Lilly and Company in a research note on Monday, September 16th. Finally, Citigroup raised their price target on shares of Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the company a “buy” rating in a research report on Friday, October 25th. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $1,013.41.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.